Search International and National Patent Collections

1. (WO2018049263) COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS

Pub. No.:    WO/2018/049263    International Application No.:    PCT/US2017/050825
Publication Date: Fri Mar 16 00:59:59 CET 2018 International Filing Date: Sat Sep 09 01:59:59 CEST 2017
IPC: A61K 39/395
C07D 413/14
A61K 45/06
C07D 311/36
C07D 405/06
C07D 413/08
C07D 413/10
C07D 473/34
C07D 473/38
C07K 16/28
Applicants: TG THERAPEUTICS, INC.
RHIZEN PHARMACEUTICALS SA
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors: WEISS, Michael S.
MISKIN, Hari P.
SPORTELLI, Peter
Title: COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS
Abstract:
The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI3 kinase (PI3K)-delta (e.g., TGR-1202); (ii) at least one anti-CD20 antibody (e.g., ublituximab); and (iii) at least one anti-PD-1 antibody (e.g., pembrolizumab) or anti-PD-L1 antibody (e.g., atezolizumab). Treatment regimens are also provided.